Antonio S. Montecalvo - Feb 21, 2024 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
Vice President, Health Policy
Signature
/s/ William R. Kolb, Attorney-in-Fact
Stock symbol
ORGO
Transactions as of
Feb 21, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 05:24 PM
Previous filing
Feb 20, 2024
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Award $0 +43.7K +34.63% $0.00 170K Feb 21, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Award $0 +79.1K $0.00 79.1K Feb 21, 2024 Class A Common Stock 79.1K $3.43 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024.
F2 The option becomes exercisable in equal annual installments over four years beginning February 15, 2024.